Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tafluprost

FDA-approved product (solution/drops, ophthalmic), marketed as Tafluprost, Zioptan.

Registered studies
37
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tafluprost
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prostaglandin analogues
FDA pharmacologic class
Prostaglandin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

37registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tafluprost in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tafluprost with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Use of an Ocular Telemetry Sensor in Tafluprost Treated Patients

    NCT01263535 · start 2010-09

    Registered record
    Registry ID
    NCT01263535
    Conditions
    Glaucoma
    Interventions
    SENSIMED Triggerfish
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-09
    Completion
    2012-05
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionSENSIMED Triggerfish
    PhasePhase 4
    Registry statusTerminated

  • The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma

    NCT01369771 · start 2010-08

    Registered record
    Registry ID
    NCT01369771
    Conditions
    Ocular Hypertension; Open-Angle Glaucoma
    Interventions
    Tafluprost 0.0015%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open-Angle Glaucoma
    InterventionTafluprost 0.0015%
    PhasePhase 4
    Registry statusCompleted

  • Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops

    NCT01087671 · start 2010-04

    Registered record
    Registry ID
    NCT01087671
    Conditions
    Ocular Hypertension; Open-Angle Glaucoma
    Interventions
    tafluprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-10
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open-Angle Glaucoma
    Interventiontafluprost
    PhasePhase 3
    Registry statusCompleted

  • Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)

    NCT01026831 · start 2010-01-06

    Registered record
    Registry ID
    NCT01026831
    Conditions
    Open-angle Glaucoma; Ocular Hypertension
    Interventions
    Preservative-Free Tafluprost; Comparator: timolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-01-06
    Completion
    2010-09-17
    Enrolment
    643

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma; Ocular Hypertension
    InterventionPreservative-Free Tafluprost; Comparator: timolol
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

    NCT00966940 · start 2009-09

    Registered record
    Registry ID
    NCT00966940
    Conditions
    Glaucoma
    Interventions
    Travoprost 0.004% ophthalmic solution (TRAVATAN); Tafluprost 0.0015% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2010-03
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionTravoprost 0.004% ophthalmic solution (TRAVATAN); Tafluprost 0.0015% ophthalmic solution
    PhasePhase 4
    Registry statusCompleted

  • Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

    NCT00596791 · start 2008-01

    Registered record
    Registry ID
    NCT00596791
    Conditions
    Ocular Hypertension; Open-Angle Glaucoma
    Interventions
    tafluprost
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-08
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Hypertension; Open-Angle Glaucoma
    Interventiontafluprost
    PhasePhase 3
    Registry statusCompleted

  • Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation

    NCT00918346 · start 2005-09

    Registered record
    Registry ID
    NCT00918346
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Tafluprost 0.0015%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-09
    Completion
    2006-04
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionTafluprost 0.0015%
    PhasePhase 3
    Registry statusCompleted